Featured Research

from universities, journals, and other organizations

Capsules Against Diabetes

Date:
June 25, 2007
Source:
Norwegian University of Science and Technology
Summary:
There is renewed hope for treatment of diabetes type 1 with gel capsules: Biotechnologists have developed a new type of alginate capsule that could solve the problem of the body's immune system recognizing and attacking alien, implanted insulin cells.

HUMAN EYE TISSUE: Clusters of insulin-producing cells marked with special chemicals that make living cells green and dead cells red. The cell clusters measure 50 to 200 micrometre.
Credit: Berit L. Strand

There is renewed hope for treatment of diabetes type 1 with gel capsules: Biotechnologists at The Norwegian University of Science and Technology (NTNU) have developed a new type of alginate capsule that could solve the problem of the body’s immune system recognizing and attacking alien, implanted insulin cells.

If this becomes a medical reality, diabetes patients with transplanted insulin-producing donor cells in their abdominal cavity do not have to take immunosuppressants for the rest of their life – medication which involves a high risk of infections and cancer.

Researchers also envision using the innovation in the treatment of certain types of cancer.

The Trondheim Capsule

The new capsule, called TAM (the Trondheim Alginate Microcapsule), is designed with a view to camouflage the insulin-producing cells to the body’s immune system.

”If the capsule is to function well, it needs to be suitably porous so that it allows nutrients to enter the insulin cells while insulin is transported out. It must be suitably small, and it must be stabile so it doesn’t swell and gradually break. We seem to be in the process of solving all these challenges," says Research Fellow Yrr Mørch from the Capsule Group at NTNU.

Her research environment, headed by Professor Gudmund Skjåk-Bræk, participates in an international cooperation called «The Chicago Project». The aim is to find a functional cure for diabetes type 1.

A solution around the corner

Alginate capsules with insulin cells are currently not used in the treatment of diabetes patients, even though the idea is far from new. As early as in the 1990s, an American had an alginate capsule with insulin cells produced in Trondheim implanted.

It appeared to be a success, but how well the old capsule actually functioned remained unanswered as the American had also had a kidney transplant and already took immunosuppressants.

Animal experiments later revealed that the capsule did not function satisfactorily. The main reason being polylysine, a substance used on the capsule’s outside to improve stability and make it less porous. This substance is toxic and triggers the immune system, which results in immune cells attaching to the capsule surface and hampering the diffusion of substances in and out of the capsule. The result is cell death.

Thorough basic research and several doctoral degrees later, the solution to the immune problem related to the transplant of capsules with insulin producing cells appears to be close. However, many years are likely to pass before the method can be used in patients. 

Tailored alginate

Alginate is a long sugar molecule that stiffens kelp in the same way as cellulose makes the trees stand upright. Kelp has been researched at NTNU/former NTH for 50 years. Several of the alginate’s secrets are therefore revealed, including its structure.

Researchers have managed to isolate, clone and produce in large scale an enzyme involved in the construction of the alginate in different ways. That means that the researchers themselves can build the nanostructure of alginate so the molecule gets the desired properties.

Researchers envision tailoring different alginate capsules for individual use in the near future.


Story Source:

The above story is based on materials provided by Norwegian University of Science and Technology. Note: Materials may be edited for content and length.


Cite This Page:

Norwegian University of Science and Technology. "Capsules Against Diabetes." ScienceDaily. ScienceDaily, 25 June 2007. <www.sciencedaily.com/releases/2007/06/070624121236.htm>.
Norwegian University of Science and Technology. (2007, June 25). Capsules Against Diabetes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/06/070624121236.htm
Norwegian University of Science and Technology. "Capsules Against Diabetes." ScienceDaily. www.sciencedaily.com/releases/2007/06/070624121236.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins